title: Is there a future for adoptive cell transfer in melanoma patients?
abstract: The adoptive transfer of tumor-infiltrating lymphocytes (TILs) can yield durable responses in patients affected by metastatic melanoma. In particular, we have recently reported an 80% 3 year survival rate among patients who responded to this immunotherapeutic regimen. Of note, overall response rates were equal among ipilimumab-naïve and ipilimumab-refractory patients. Thus, the adoptive transfer of TILs, as a standalone therapeutic intervention or combined with other treatment modalities, bears a high clinical potential that must be optimally employed.
authors.affiliation: Ella Institute of Melanoma; Sheba Medical Center; Ramat Gan and Department of Clinical Microbiology and Immunology; Sackler School of Medicine; Tel Aviv University; Israel.
authors.forename: Michal J
authors.initials: MJ
authors.lastname: Besser
keywords: adoptive cell transfer; immunotherapy; ipilimumab; melanoma; tumor-infiltrating lymphocytes